Mostrar el registro sencillo del ítem

Artículo

dc.creatorLazarus, J. V.es
dc.creatorPalayew, A.es
dc.creatorCarrieri, P.es
dc.creatorEkstedt, M.es
dc.creatorMarchesini, G.es
dc.creatorNovak, K.es
dc.creatorRatziu, V.es
dc.creatorRomero Gómez, Manueles
dc.creatorAnstee, Q. M.es
dc.date.accessioned2022-11-09T15:08:42Z
dc.date.available2022-11-09T15:08:42Z
dc.date.issued2021
dc.identifier.citationLazarus, J.V., Palayew, A., Carrieri, P., Ekstedt, M., Marchesini, G., Novak, K.,...,Anstee, Q.M. (2021). European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 3 (2), 100234. https://doi.org/10.1016/j.jhepr.2021.100234.
dc.identifier.issn2589-5559es
dc.identifier.urihttps://hdl.handle.net/11441/139186
dc.description.abstractBackground & Aims: Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe. Methods: In June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100. Results: The analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management. Conclusions: The NAFLD Preparedness Index indicates substantial variation between countries’ readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place. Lay summary: Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied.es
dc.formatapplication/pdfes
dc.format.extent8 p.es
dc.language.isoenges
dc.publisherElsevier BVes
dc.relation.ispartofJHEP Reports, 3 (2), 100234.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectNon-alcoholic fatty liver diseasees
dc.subjectLiver healthes
dc.subjectMultiple joint correspondence analysises
dc.subjectPolicy preparednesses
dc.subjectHealth policyes
dc.subjectMetabolic-associated fatty liver diseasees
dc.subjectNon-alcoholic steatohepatitises
dc.subjectEuropees
dc.titleEuropean 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?es
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDCP18/00074es
dc.relation.projectIDCEX2018-000806-Ses
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2589555921000100?via%3Dihubes
dc.identifier.doi10.1016/j.jhepr.2021.100234es
dc.journaltitleJHEP Reportses
dc.publication.volumen3es
dc.publication.issue2es
dc.publication.initialPage100234es
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades de Españaes

FicherosTamañoFormatoVerDescripción
European...pdf327.6KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional